Regeneron Pharmaceuticals is expanding its cell therapy research, announcing a deal Tuesday to acquire the drug pipeline of 2seventy Bio and bring on many of the smaller biotechnology company’s employees.
The experimental cell therapies Regeneron acquires will be housed in a newly created research and development unit called Regeneron Cell Medicines, to be led by 2seventy’s top scientist Phil Gregory. Approximately 150 staff from 2seventy will join Gregory in transitioning to Regeneron.
